New findings from a study by Merck KGaA, Darmstaft, Germany, a science and technology company operating as EMD Serono in Canada has shown that Cladribine Tablets can reduce brain atrophy, the rate of brain volume loss.
The use of Clabribine Tablets was tested against a placebo in patients with relapsing remitting multiple sclerosis (RRMS). Experts said that the primary endpoint was the relapse rate of over 96 weeks; while the secondary endpoints were noted to have included MRI endpoints, proportion of subjects relapse-free, as well as disability progression at 96 weeks.
According to reports revealed by CNW Online, experts have revealed that Cladribine Tablets is an investigational short-course oral therapy that selectively and periodically targets lymphocytes that are thought to be integral to the pathological process of MS. Cladribine Tablets is under clinical investigation and has not yet been approved for the treatment for any use in the United States, Canada and Europe.
In a statement reported by MPR Online, study lead author and associate professor of neurology at the University of Siena, Nicola De Stefano said that the analysis obtained in the their study plays an important role because it confirms the link between reduced brain atrophy and reduced disability progression found in the study. The associate professor also said that the findings support the existing research which indicates that increased brain volume loss over time is associated with worse clinical outcomes, such as increased disability progression and cognitive changes, particularly in MS patients.
Source: MS-UK (15/02/17)